Gradated Risk Rating System for Pharmaceutical Safety Communication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical and medical device labeling systems do not effectively communicate risk information to consumers in a comprehensible manner, as they rely on binary warnings and do not account for the varying levels of risk associated with different populations or the evolving safety profiles of drugs over time.
Innovation Solution
A method and system for assigning a gradated risk rating to medical products, including pharmaceuticals, biologics, and medical devices, based on assessed threats, severity, probability, and population impact, using an algorithm that pools individual threat ratings and considers the level of experience with the product, providing a visually understandable risk indication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If traditional FDA-approved labeling with black box warnings is used, then safety information is provided to patients, but the information is not readily comprehendible and does not adequately inform patients of which adverse events apply to them individually
Solution Approach 1:
The patent segments the comprehensive safety information into discrete, manageable risk factors that can be individually assessed and communicated. Each risk factor is evaluated separately based on severity, probability, and population impact, then synthesized into an overall risk rating. This segmentation makes the information more comprehendible for patients while maintaining systematic completeness.
Solution Approach 2:
The patent transforms safety information from qualitative descriptive text into quantitative risk ratings using defined parameters (severity, probability, population impact). This parameterization enables numerical comparison and gradation of risks, making them more comprehensible and actionable for patients and providers.
2Measurement precision
If black box warnings are used to highlight serious threats, then prominent safety alerts are provided, but the warnings are binary indicators that do not reflect varying levels of risk or population-specific concerns
Solution Approach 1:
The patent implements a dynamic, multi-level risk rating system that adapts to different drugs, populations, and risk scenarios. Rather than a static binary warning, the system provides graduated risk levels (e.g., low, moderate, high, very high) that dynamically reflect the specific characteristics of each drug-population-risk combination, enabling more precise risk communication.
Solution Approach 2:
The patent adds dimensional granularity to risk communication by introducing multiple assessment dimensions (severity, probability, population impact) and combining them into an overall risk rating. This multi-dimensional approach transforms the flat binary warning into a nuanced, layered risk assessment that preserves simplicity while enhancing precision.
3Loss of information
If comprehensive safety information from clinical studies is included in labels, then complete safety profiles are provided, but the information becomes overwhelming and is unlikely to inform the patient as to how the label applies to them
Solution Approach 1:
The patent extracts the most critical safety information from comprehensive clinical study data and focuses communication on key risk factors most relevant to patient decision-making. By selecting and prioritizing essential risk elements rather than presenting all available data, the system maintains information completeness while dramatically improving usability and patient comprehension.
Solution Approach 2:
The patent introduces an intermediary risk rating system that translates complex clinical safety data into patient-friendly risk assessments. This intermediary layer processes comprehensive safety information through defined evaluation criteria and presents the results in an accessible format, bridging the gap between detailed scientific data and patient understanding.
4Measurement precision
If risk information is provided based on drug class rather than individual drug, then broader safety patterns are identified, but the information does not capture the different levels of risk associated with individual drugs
Solution Approach 1:
The patent applies local quality assessment by evaluating risk factors at the individual drug level while considering class-level patterns. Each drug receives a customized risk rating based on its specific clinical data, population characteristics, and risk profile, rather than applying uniform class-wide assessments. This enables precise, drug-specific risk communication while leveraging broader class knowledge where appropriate.
Data Source
AI summary
The invention relates to a method for assigning a risk rating to a medical product. The method includes assessing one or more threats associated with the medical product; assessing the level of experience with the medical product; and assigning a risk rating for the medical product to provide an indication of risk associated with the medical product. The method may be implemented as a webpage. For example, a new contraceptive may be assigned a risk rating of yellow for the general treatment population. This risk rating allows consumers to make an informed choice between different products on the basis of benefit versus risk, and help patients decide what steps they may wish to take to minimize their risk if they choose to take the new drug.